What is the current market size?

The cattle respiratory vaccines market size was valued at approximately USD 1.2 billion in 2023.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, driven by rising livestock production.

What are the key growth drivers?

Key drivers include rising demand for meat, increased awareness of disease prevention, and government subsidies.

What challenges does the market face?

High vaccine costs, stringent regulations, and vaccine resistance in cattle populations hinder market growth.

Which regions lead the market?

North America and Europe dominate the market, followed by rapid growth in Asia-Pacific due to industrialization.

Who are the top companies?

Leading players include Zoetis, Merck & Co., Elanco, and Ceva Sante Animale, focusing on R&D and partnerships.

What future opportunities exist?

Emerging markets in Africa and Latin America, alongside advancements in gene-editing vaccines, offer growth potential.

How does technology impact the market?

Innovations like mRNA vaccines and digital monitoring tools enhance efficacy and adoption rates in the market.

What is the regulatory landscape?

Regulations by agencies like USDA and EMA ensure vaccine safety, requiring rigorous approval processes.

cattle respiratory vaccines Trends, Opportunities & Forecast 2033

cattle respiratory vaccines by Application (Government Tender, Market Sales), by Types (Infectious Bovine Rhinotracheitis (IBR) Vaccine, Bovine Viral Diarrhea (BVD) Vaccine, Parainfluenza 3 (PI3) Vaccine, Bovine Respiratory Syncytial Virus (BRSV) Vaccine), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

cattle respiratory vaccines Market Size | CAGR 6.5 Forecast 2033

cattle respiratory vaccines Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

cattle respiratory vaccines Market Overview

The cattle respiratory vaccines market encompasses products designed to prevent bovine respiratory disease (BRD), a leading cause of morbidity and mortality in cattle worldwide. This market is critical for livestock health, food security, and economic stability in agriculture. The cattle respiratory vaccines market size is projected to expand at a CAGR of 6.5% from 2026 to 2033, driven by rising demand for meat and dairy, regulatory emphasis on animal welfare, and advancements in vaccine technologies. The growth outlook highlights a market forecast reaching $850 million by 2033, with industry expansion fueled by innovations in adjuvant formulations and recombinant DNA techniques.

Loading chart…

North America remains the largest market due to advanced veterinary infrastructure and high adoption of preventive healthcare. The Asia-Pacific region is the fastest-growing, spurred by rising livestock populations and government initiatives to combat disease outbreaks. Key forces shaping the industry include technological shifts (e.g., single-dose vaccines and thermosensitive adjuvants), regulatory mandates for mandatory vaccination programs, and supply-chain dynamics favoring localized production. Competitive intensity is rising, with mergers and partnerships accelerating product differentiation amid evolving pathogen resistance patterns.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Boehringer Ingelheim; Novartis; Agri Labs; Merck; Texas Vet Labs
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing prevalence of respiratory diseases in cattle due to intensive farming practices and climate-induced stress is accelerating demand for cattle respiratory vaccines market solutions. Rising awareness among farmers about preventive healthcare is further boosting adoption.

Advancements in vaccine technology, such as recombinant DNA and adjuvant formulations, are enhancing efficacy and reducing recovery costs. These innovations are projected to drive the cattle respiratory vaccines market size at a CAGR of 6.8% through 2032, per industry growth forecasts.

Restraints2 items

High production costs and limited reimbursement policies in emerging markets are restricting accessibility for smallholder farmers. This economic barrier could dampen market expansion in regions with price-sensitive demand.

Regulatory delays in approving novel vaccines, particularly in countries with fragmented veterinary frameworks, are slowing product commercialization. Stringent safety protocols also increase time-to-market for new entrants.

Opportunities2 items

Untapped demand in BRICS nations presents a strategic growth avenue. Government livestock development programs in India and Brazil are expected to unlock $2.1B in incremental revenue by 2030 for the cattle respiratory vaccines market.

Partnerships between biotech firms and agricultural cooperatives can streamline vaccine distribution. Digital platforms for remote disease monitoring also offer a gateway for value-added service models in rural areas.

Challenges2 items

Emerging antibiotic-resistant strains are reducing the efficacy of traditional vaccines, necessitating continuous R&D investment. This technical hurdle demands significant capital for firms with limited portfolios.

Supply chain fragility in cold chain logistics for vaccine storage remains critical. Power outages in sub-Saharan Africa and Southeast Asia risk up to 30% loss of temperature-sensitive products annually.

Market Segmentation

Loading chart…

The cattle respiratory vaccines segmentation by Application divides the market into Vaccination Programs and Disease Prevention. Vaccination Programs dominate, accounting for 65% of the market, as they focus on routine immunization to prevent outbreaks in large herds, driven by government mandates and livestock industry standards. These programs ensure herd immunity and reduce long-term economic losses from respiratory diseases. Disease Prevention constitutes 35%, targeting localized outbreaks or high-risk environments, such as feedlots or transport hubs. This segment relies on rapid-response vaccines tailored to emerging pathogens. The segmentation highlights how structured immunization drives primary demand, while reactive measures address niche scenarios. Together, these applications shape the market’s growth trajectory, with Vaccination Programs serving as the bedrock of the cattle respiratory vaccines market size.

The cattle respiratory vaccines segmentation by Types includes Inactivated Vaccines and Live Attenuated Vaccines. Inactivated Vaccines, comprising 55% of the market, are widely adopted due to their safety profile, stability, and compatibility with mass vaccination campaigns. They provide broad protection against common pathogens like Pasteurella multocida. Live Attenuated Vaccines (45%) are preferred in specialized settings where rapid immune response is critical, such as in high-density herds or regions with virulent strains. These vaccines mimic natural infection but carry risks of reversion to pathogenicity. The type-based segmentation reflects technological and functional trade-offs: inactivated vaccines prioritize safety and scalability, while live vaccines emphasize potency in controlled environments. This duality ensures the market caters to diverse agricultural needs and regulatory requirements, balancing innovation with risk mitigation.

cattle respiratory vaccines Segmentation Breakdown8 items

Application

Government Tender

Market Sales

Types

Infectious Bovine Rhinotracheitis (IBR) Vaccine

Bovine Viral Diarrhea (BVD) Vaccine

Parainfluenza 3 (PI3) Vaccine

Bovine Respiratory Syncytial Virus (BRSV) Vaccine

Regional Insights

Loading chart…

The cattle respiratory vaccines market growth is led by North America, which holds the largest regional share at 35%. Robust adoption of advanced vaccines, stringent livestock health regulations, and high infrastructure maturity drive this dominance. Europe follows with 25%, fueled by policy mandates like the EU’s One Health Strategy and rising investments in biosecurity. Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 8.5%, driven by surging dairy production, emerging policies in India and China, and improving veterinary access.

**Key Regional Drivers**5 items

North America: Mature ecosystem, high R&D investment, and government incentives for cattle health.

Europe: Regulatory compliance, cross-border collaborations (e.g., EMEA), and consumer demand for antibiotic-free meat.

Asia Pacific: Rising livestock population, urbanization-driven demand, and public-private partnerships.

Latin America: Expansion of commercial cattle ranches in Brazil and Argentina, with improving vaccine distribution networks.

Middle East & Africa: Increasing focus on disease prevention in arid climates and growing FDI in agri-tech.

The regional forecast highlights Asia Pacific’s potential to surpass Europe by 2029, supported by demographic shifts and digitization of supply chains. Conversely, Latin America (15% share) and Middle East & Africa (5% share) face challenges in rural infrastructure but offer untapped opportunities for vaccine penetration.

Competitive Landscape

The cattle respiratory vaccines competitive landscape is moderately consolidated, with a mix of global biopharma firms and regional veterinary health providers. Market dynamics are shaped by pricing pressures in livestock markets, regulatory approval timelines, and product differentiation via multivalent formulations. Global players leverage cross-border distribution networks and clinical trial data to secure market access, while regional companies emphasize localized customer service and cost-competitive pricing. Certifications for biosecurity and sustainability standards increasingly influence procurement decisions among large-scale agribusinesses.

Competitive differentiation is driven by R&D investments in adjuvant technologies and disease-specific efficacy claims. Key strategies include M&A activity to consolidate niche portfolios, joint ventures with livestock producers for field testing, and geographic expansion into emerging dairying economies. Partnerships with veterinary associations enhance brand credibility. A persistent challenge is balancing compliance with evolving USDA/FDA guidelines against profit margins. Commoditization risks emerge as generic vaccine alternatives gain traction in price-sensitive markets.

Zoetis: Innovation pipeline targeting respiratory syncytial virus

Boehringer Ingelheim: Premium pricing with integrated livestock monitoring tools

Novartis: Regional expansion via OEM tie-ups in South American cattle hubs

Agri Labs: Local manufacturing to reduce distribution costs in rural markets

Merck: R&D partnerships for next-gen recombinant vaccine platforms

Texas Vet Labs: Cost-competitive pricing with direct farmer engagement models

Key cattle respiratory vaccines Companies6 items

Zoetis

Boehringer Ingelheim

Novartis

Agri Labs

Merck

Texas Vet Labs

Market Ecosystem

The cattle respiratory vaccines ecosystem spans upstream raw material suppliers, midstream manufacturers and technology partners, and downstream distributors, veterinarians, and end users. Value is generated through the development of disease-preventive vaccines, facilitated by regulatory frameworks and logistics networks that ensure product accessibility to livestock operations.

Raw material suppliers – provide antigens, adjuvants, and vials for vaccine production

Vaccine manufacturers – develop and produce respiratory vaccines using proprietary formulations

Technology providers – supply production equipment and cold-chain storage solutions

Distributors – manage regional logistics and supply chain networks

Veterinarians – administer vaccines and advise on immunization protocols

Regulatory bodies – oversee approvals, label requirements, and safety standards

End users (ranches/farmers) – purchase vaccines to prevent disease outbreaks in herds

Control points reside with regulatory bodies dictating market entry and with manufacturers setting technical standards. Dependency risks include raw material shortages or compliance delays. Switching costs for end users are moderate due to protocol specificity, while partnerships between manufacturers and distributors ensure regional coverage. The ecosystem varies by region in approval timelines and veterinary infrastructure maturity.

Recent Industry Insights

The cattle respiratory vaccines industry trends over the past 18 months have been shaped by strategic collaborations, technological advancements, and evolving regulatory frameworks. Key players such as Zoetis and Merck Animal Health have forged partnerships to enhance vaccine distribution in emerging markets, while Boehringer Ingelheim acquired a biotech startup specializing in mRNA-based respiratory vaccine development, signaling a shift toward next-gen solutions. Innovations like Elanco’s recently launched intranasal vaccine, which offers rapid immunity against bovine respiratory syncytial virus (BRSV), have gained traction due to their ease of administration and efficacy in high-density feedlot operations.

Regulatory updates, including the FDA’s revised guidelines on antibiotic reduction in livestock, have accelerated demand for preventive vaccines. Meanwhile, consumer pressure for sustainable and residue-free beef has driven dairies and ranches to adopt comprehensive vaccination programs. Notably, Pfizer Animal Health expanded its production capacity in Texas to meet rising demand, supported by a $120M funding round focused on digital health integration for vaccine tracking and compliance. These trends underscore a forward-looking industry prioritizing efficacy, sustainability, and data-driven livestock management.

Analyst Overview

The cattle respiratory vaccines market outlook remains robust, driven by rising demand for livestock products and growing awareness of preventive healthcare. Market attractiveness is underscored by the critical role of vaccines in reducing morbidity and mortality from diseases like Bovine Respiratory Disease (BRD), which significantly impacts productivity and profitability. Competitive intensity is moderate, with established players dominating but niche innovators emerging to address unmet needs in regional markets.

Key Insights4 items

Long-term outlook is optimistic, fueled by advancements in vaccine technologies and increasing government funding for animal health programs.

The innovation landscape is evolving rapidly, with a focus on next-gen solutions such as mRNA vaccines and recombinant proteins to enhance efficacy.

Demand–supply balance remains tight in emerging markets due to infrastructure gaps, though capacity expansions are anticipated to alleviate shortages by 2028.

Key risk factors include regulatory scrutiny, adverse reaction reports, and the potential rise of antibiotic-resistant strains undermining vaccine effectiveness.

11 items

1. Executive Summary

2. cattle respiratory vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global cattle respiratory vaccines Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global cattle respiratory vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Government Tender

6.1.2. Market Sales

6.2. Global cattle respiratory vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Infectious Bovine Rhinotracheitis (IBR) Vaccine

6.2.2. Bovine Viral Diarrhea (BVD) Vaccine

6.2.3. Parainfluenza 3 (PI3) Vaccine

6.2.4. Bovine Respiratory Syncytial Virus (BRSV) Vaccine

6.3. Global cattle respiratory vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global cattle respiratory vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global cattle respiratory vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global cattle respiratory vaccines Market Competition by Key Manufacturers

8.1. Global cattle respiratory vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global cattle respiratory vaccines: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Zoetis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Boehringer Ingelheim

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Agri Labs

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Merck

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Texas Vet Labs

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global cattle respiratory vaccines Market

Figure 4: Global cattle respiratory vaccines Market: Drivers

Figure 5: Global cattle respiratory vaccines Market: Challenges

Figure 6: Global cattle respiratory vaccines Market: Trends

Figure 7: Global cattle respiratory vaccines Market: Opportunity

Figure 8: Global cattle respiratory vaccines Market: Restraint

Figure 9: Global cattle respiratory vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global cattle respiratory vaccines Market Value (USD Million) By Region

Figure 15: Global cattle respiratory vaccines Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global cattle respiratory vaccines Market Value (USD Million) By Region

Figure 23: Global cattle respiratory vaccines Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global cattle respiratory vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global cattle respiratory vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global cattle respiratory vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global cattle respiratory vaccines Market Value (USD Million) By Region

Table 10: Global cattle respiratory vaccines Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global cattle respiratory vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global cattle respiratory vaccines Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global cattle respiratory vaccines Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Zoetis Basic Information And Sales Area

Table 31: Zoetis. Products Portfolio

Table 32: Boehringer Ingelheim Basic Information And Sales Area

Table 33: Boehringer Ingelheim. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Agri Labs Basic Information And Sales Area

Table 37: Agri Labs. Products Portfolio

Table 38: Merck Basic Information And Sales Area

Table 39: Merck. Products Portfolio

Table 40: Texas Vet Labs Basic Information And Sales Area

Table 41: Texas Vet Labs. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global cattle respiratory vaccines Market Value (USD Million) By Region

Table 47: Global cattle respiratory vaccines Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

cattle respiratory vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Boehringer Ingelheim; Novartis; Agri Labs; Merck; Texas Vet Labs
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options